What is the current valuation of the US thalassemia treatment market as of 2024?

The market valuation was $1744.95 Million in 2024. Read More

What is the projected market valuation for the US thalassemia treatment market in 2035?

The projected valuation for 2035 is $2512.51 Million. Read More

What is the expected CAGR for the US thalassemia treatment market during the forecast period 2025 - 2035?

The expected CAGR during this period is 3.37%. Read More

Which companies are the key players in the US thalassemia treatment market?

Key players include Novartis, Bristol-Myers Squibb, Roche, Amgen, Pfizer, Bluebird Bio, Celgene, GSK, and Bayer. Read More

What are the main segments of the US thalassemia treatment market?

The main segments include Type, Route of Administration, Patient Age Group, and Therapeutic Area. Read More

How much revenue did Blood Transfusion generate in the US thalassemia treatment market in 2024?

Blood Transfusion generated between $400.0 Million and $600.0 Million in 2024. Read More

What is the revenue range for Gene Therapy in the US thalassemia treatment market?

Gene Therapy is projected to generate between $500.0 Million and $800.0 Million. Read More

What is the revenue range for the Pediatric age group in the US thalassemia treatment market?

The Pediatric age group generated between $300.0 Million and $450.0 Million in 2024. Read More

Which route of administration had the highest revenue in the US thalassemia treatment market?

The Subcutaneous route had a revenue range of $644.95 Million to $962.51 Million. Read More

What revenue did the Oncology therapeutic area generate in the US thalassemia treatment market?

The Oncology therapeutic area generated between $500.0 Million and $700.0 Million. Read More

US Thalassemia Treatment Market

ID: MRFR/HC/17999-HCR

100 Pages

Vikita Thakur

Last Updated: April 06, 2026

US Thalassemia Treatment Market Research Report By Treatment Type (Blood Transfusion, Chelation Therapy, Bone Marrow Transplantation, Gene Therapy, Supportive Care), By Route of Administration (Intravenous, Oral, Subcutaneous), By Patient Age Group (Pediatric, Adult, Geriatric) and By Therapeutic Area (Hematology, Oncology, Immunology) - Growth & Industry Forecast 2025 To 2035

US Thalassemia Treatment Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Type (USD Million)
  1. 4.1.1 Blood Transfusion
  2. 4.1.2 Chelation Therapy
  3. 4.1.3 Bone Marrow Transplantation
  4. 4.1.4 Gene Therapy
  5. 4.1.5 Supportive Care
2. 4.2 Chemicals and Materials, BY Route of Administration (USD Million)
  1. 4.2.1 Intravenous
  2. 4.2.2 Oral
  3. 4.2.3 Subcutaneous
3. 4.3 Chemicals and Materials, BY Patient Age Group (USD Million)
  1. 4.3.1 Pediatric
  2. 4.3.2 Adult
  3. 4.3.3 Geriatric
4. 4.4 Chemicals and Materials, BY Therapeutic Area (USD Million)
  1. 4.4.1 Hematology
  2. 4.4.2 Oncology
  3. 4.4.3 Immunology
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Roche (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Amgen (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Bluebird Bio (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Celgene (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 GSK (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Bayer (DE)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
4. 6.4 US MARKET ANALYSIS BY PATIENT AGE GROUP
5. 6.5 US MARKET ANALYSIS BY THERAPEUTIC AREA
6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
12. 6.12 CHEMICALS AND MATERIALS, BY TYPE, 2024 (% SHARE)
13. 6.13 CHEMICALS AND MATERIALS, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
15. 6.15 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
16. 6.16 CHEMICALS AND MATERIALS, BY PATIENT AGE GROUP, 2024 (% SHARE)
17. 6.17 CHEMICALS AND MATERIALS, BY PATIENT AGE GROUP, 2024 TO 2035 (USD Million)
18. 6.18 CHEMICALS AND MATERIALS, BY THERAPEUTIC AREA, 2024 (% SHARE)
19. 6.19 CHEMICALS AND MATERIALS, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.2.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.2.4 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Chemicals and Materials Market Segmentation

Chemicals and Materials By Type (USD Million, 2025-2035)

Blood Transfusion
Chelation Therapy
Bone Marrow Transplantation
Gene Therapy
Supportive Care

Chemicals and Materials By Route of Administration (USD Million, 2025-2035)

Intravenous
Oral
Subcutaneous

Chemicals and Materials By Patient Age Group (USD Million, 2025-2035)

Pediatric
Adult
Geriatric

Chemicals and Materials By Therapeutic Area (USD Million, 2025-2035)

Hematology
Oncology
Immunology

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”